Hereditary Angioedema (HAE) Treatment Market Size to touch USD 4.9 Billion by 2027
Acumen Research and Consulting has announced the addition of the “Hereditary Angioedema (HAE) Treatment Market” report to their offering.
The Hereditary Angioedema (HAE) Treatment Market Industry Report 2030 is an in depth study analyzing the current state of the Hereditary Angioedema (HAE) Treatment Market. It provides brief overview of the market focusing on definitions, market segmentation, end-use applications and industry chain analysis. The study on Hereditary Angioedema (HAE) Treatment Market provides analysis of China market covering the industry trends, recent developments in the market and competitive landscape. Competitive analysis includes competitive information of leading players in China market, their company profiles, product portfolio, capacity, production, and company financials. In addition, report also provides upstream raw material analysis and downstream demand analysis along with the key development trends and sales channel analysis. Research study on Hereditary Angioedema (HAE) Treatment Market also discusses the opportunity areas for investors.
Download Sample Report Copy From Here:https://www.acumenresearchandconsulting.com/request-sample/2460
The report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
Key companies profiled in this report involve BIOCRYST PHARMACEUTICALS, INC., Ionis Pharmaceuticals, Pharming Group NV, CSL Limited, Takeda Pharmaceutical Company Limited., Attune Pharmaceuticals., Adverum Biotechnologies, Inc., and KalVista Pharmaceuticals, and among others.
Market Segmentation:
Market By Drug Class
C1-esterase inhibitor
Bradykinin B2 receptor antagonist
Kallikrein inhibitor
Others
Market By Treatment Type
Prophylaxis
On-demand
Market By Route of Administration
Intravenous
Subcutaneous
Oral
Table Of Contents:
CHAPTER 1. Industry Overview of Hereditary Angioedema (HAE) Treatment
1.1. Definition and Scope
1.1.1. Definition of Hereditary Angioedema (HAE) Treatment
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Hereditary Angioedema (HAE) Treatment Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Hereditary Angioedema (HAE) Treatment Market By Drug Class
1.2.3. Hereditary Angioedema (HAE) Treatment Market By Treatment Type
1.2.4. Hereditary Angioedema (HAE) Treatment Market By Route of Administration
1.2.5. Hereditary Angioedema (HAE) Treatment Market by Regions
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Hereditary Angioedema (HAE) Treatment Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Hereditary Angioedema (HAE) Treatment Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Price Trend of Key Raw Materials
3.8.2. Raw Material Suppliers
3.8.3. Proportion of Manufacturing Cost Structure
3.8.3.1. Raw Material
3.8.3.2. Labor Cost
3.8.3.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2019
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2019
4.2. R&D Status and Application Source of Hereditary Angioedema (HAE) Treatment Major Manufacturers in 2019
CHAPTER 5. Hereditary Angioedema (HAE) Treatment Market By Drug Class
5.1. Introduction
5.2. Hereditary Angioedema (HAE) Treatment Revenue By Drug Class
5.2.1. Hereditary Angioedema (HAE) Treatment Revenue (US$ Mn) and Forecast, By Drug Class, 2016-2027
5.2.2. C1-esterase inhibitor
5.2.2.1. C1-esterase inhibitor Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3. Bradykinin B2 receptor antagonist
5.2.3.1. Bradykinin B2 receptor antagonist Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.4. Kallikrein inhibitor
5.2.4.1. Kallikrein inhibitor Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.5. Others
5.2.5.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 6. Hereditary Angioedema (HAE) Treatment Market Revenue By Treatment Type
6.1. Introduction
6.2. Hereditary Angioedema (HAE) Treatment Revenue (US$ Mn) By Treatment Type
6.2.1. Hereditary Angioedema (HAE) Treatment Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
6.2.2. Prophylaxis
6.2.2.1. Prophylaxis Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.3. On-demand
6.2.3.1. On-demand Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 7. Hereditary Angioedema (HAE) Treatment Market By Route of Administration
7.1. Introduction
7.2. Hereditary Angioedema (HAE) Treatment Revenue (US$ Mn) By Route of Administration
7.2.1. Hereditary Angioedema (HAE) Treatment Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
7.2.2. Intravenous
7.2.2.1. Intravenous Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.3. Subcutaneous
7.2.3.1. Subcutaneous Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.4. Oral
7.2.4.1. Oral Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 8. North America Hereditary Angioedema (HAE) Treatment Market By Country
8.1. North America Hereditary Angioedema (HAE) Treatment Overview
8.2. U.S.
8.2.1. U.S. Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
8.2.2. U.S. Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
8.2.3. U.S. Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
8.3. Canada
8.3.1. Canada Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
8.3.2. Canada Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
8.3.3. Canada Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
8.4. North America PEST Analysis
CHAPTER 9. Europe Hereditary Angioedema (HAE) Treatment Market By Country
9.1. Europe Hereditary Angioedema (HAE) Treatment Market Overview
9.2. U.K.
9.2.1. U.K. Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.2.2. U.K. Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
9.2.3. U.K. Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
9.3. Germany
9.3.1. Germany Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.3.2. Germany Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
9.3.3. Germany Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
9.4. France
9.4.1. France Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.4.2. France Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
9.4.3. France Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
9.5. Spain
9.5.1. Spain Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.5.2. Spain Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
9.5.3. Spain Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
9.6. Rest of Europe
9.6.1. Rest of Europe Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.6.2. Rest of Europe Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
9.6.3. Rest of Europe Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Hereditary Angioedema (HAE) Treatment Market By Country
10.1. Asia Pacific Hereditary Angioedema (HAE) Treatment Market Overview
10.2. China
10.2.1. China Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
10.2.2. China Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
10.2.3. China Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
10.3. Japan
10.3.1. Japan Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
10.3.2. Japan Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
10.3.3. Japan Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
10.4. India
10.4.1. India Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
10.4.2. India Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
10.4.3. India Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
10.5. Australia
10.5.1. Australia Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
10.5.2. Australia Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
10.5.3. Australia Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
10.6. South Korea
10.6.1. South Korea Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
10.6.2. South Korea Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
10.6.3. South Korea Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
10.7.2. Rest of Asia-Pacific Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
10.7.3. Rest of Asia-Pacific Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Hereditary Angioedema (HAE) Treatment Market By Country
11.1. Latin America Hereditary Angioedema (HAE) Treatment Market Overview
11.2. Brazil
11.2.1. Brazil Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
11.2.2. Brazil Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
11.2.3. Brazil Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
11.3. Mexico
11.3.1. Mexico Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
11.3.2. Mexico Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
11.3.3. Mexico Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
11.4. Rest of Latin America
11.4.1. Rest of Latin America Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
11.4.2. Rest of Latin America Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
11.4.3. Rest of Latin America Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
CHAPTER 12. Middle East & Africa Hereditary Angioedema (HAE) Treatment Market By Country
12.1. Middle East & Africa Hereditary Angioedema (HAE) Treatment Market Overview
12.2. Saudi Arabia
12.2.1. Saudi Arabia Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
12.2.2. Saudi Arabia Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
12.2.3. Saudi Arabia Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
12.3. UAE
12.3.1. UAE Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
12.3.2. UAE Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
12.3.3. UAE Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
12.4.2. Rest of Middle East & Africa Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
12.4.3. Rest of Middle East & Africa Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 – 2027
CHAPTER 13. Player Analysis Of Hereditary Angioedema (HAE) Treatment
13.1. Hereditary Angioedema (HAE) Treatment Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Hereditary Angioedema (HAE) Treatment Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14. COMPANY PROFILE
14.1. BIOCRYST PHARMACEUTICALS, INC.
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (US$ Mn), 2019
14.1.3.2. BIOCRYST PHARMACEUTICALS, INC. 2019 Hereditary Angioedema (HAE) Treatment Business Regional Distribution
14.1.4. Product/ Service and Specification
14.1.5. Recent Developments & Business Strategy
14.1.6. Manufacturing Plant Footprint Analysis
14.2. Ionis Pharmaceuticals
14.3. Pharming Group NV
14.4. CSL Limited
14.5. Takeda Pharmaceutical Company Limited.
14.6. Attune Pharmaceuticals.
14.7. Adverum Biotechnologies, Inc.
14.8. KalVista Pharmaceuticals
14.9. Others
Ask Query Here: Richard@acumenresearchandconsulting.com or sales@acumenresearchandconsulting.com
To Purchase this Premium Report@https://www.acumenresearchandconsulting.com/buy-now/0/2460
About Us:
Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.
